SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Careers
Contact Us
Expanded Access Policy
Diabetes
Products
Manufacturing
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Financial Calendar
Skip Navigation Links
Home
»
Investors
»
Press Releases
Diamyd Medical’s financial year comprises 1 September – 31 August.
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Data pager
Data pager
1
2
3
4
Show:
PageSizeComboBox
select
10
20
50
100
150
4 pages
Press Releases
Data pager
Data pager
1
2
3
4
Show:
PageSizeComboBox
select
10
20
50
100
150
4 pages
11/15/2024
Conference on the future of Type 1 Diabetes screening organized as part of the ASSET partnership coordinated by Diamyd Medical
11/14/2024
Diamyd Medical recognizes World Diabetes Day
11/14/2024
Information about the Annual Report 2023/2024
11/6/2024
In-depth analysis showing robust Diamyd
®
treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress
11/5/2024
Diamyd Medical and INNODIA partner for Type 1 Diabetes awareness and patient recruitment for the DIAGNODE-3 precision medicine trial
10/14/2024
Diamyd Medical highlights precision medicine approach for Type 1 Diabetes at the scientific conferences ISPAD and IDS
10/9/2024
Year-End Report 23/24
10/2/2024
Diamyd Medical announces final outcome of the exercise of series TO 3 warrants
9/25/2024
The last day of trading in Diamyd Medical's warrants of series TO 3 is today
9/9/2024
Diamyd Medical to pursue accelerated approval pathway for Type 1 Diabetes precision medicine
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
|
Expanded Access Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research